Syncom Formulations (India) Ltd (SYNCOMF)

Healthcare · Pharmaceuticals · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹20.07 ↑ 18.48% (1Y)

🎯 Key Takeaways

Syncom Formulations (India) Ltd is in a phase of leadership transition following the resignation of its founding family executives — Kedarmal Bankda, Managing Director Vijay Bankda, and CFO Rahul Bankda — with succession planned through appointments of Rinki Ankit Bankda as Whole-time Director and Managing Director, and Ankur Vijay Bankda as CFO. The company maintains strong profitability metrics, including ROE of 25% and ROCE of 32.
Revenue declined 7.3% QoQ to ₹126 in Q1FY27.
⚠️ Execution risk stemming from leadership transition — new Whole-time Director and CFO lack a track record of disclosed operational performance, and the

Market Cap

₹1,887

P/E Ratio

22.1

P/B Ratio

5.51

ROE

25.0%

ROCE

32.9%

Debt/Equity

0.01

Promoter

50.6%

✨ Ask AI About SYNCOMF 📊 Interactive Charts

📖 The Story

Syncom Formulations (India) Ltd is in a phase of leadership transition following the resignation of its founding family executives — Kedarmal Bankda, Managing Director Vijay Bankda, and CFO Rahul Bankda — with succession planned through appointments of Rinki Ankit Bankda as Whole-time Director and Managing Director, and Ankur Vijay Bankda as CFO. The company maintains strong profitability metrics, including ROE of 25% and ROCE of 32.9%, and a near-zero debt profile, reflecting a financially resilient structure. However, the leadership change introduces near-term execution uncertainty, particularly as new directors require shareholder approval at the upcoming AGM. The business remains cash-generative and profitable, but its trajectory hinges on the operational continuity and strategic clarity provided by the new leadership team.

📰 What's Happening

In August 2026, Syncom Formulations executed a planned board reshuffle, accepting the resignations of three senior executives from the Bankda family and appointing Rinki Ankit Bankda as Whole-time Director and Managing Director, Ankur Vijay Bankda as CFO, and reappointing Ruchi Jindal as Woman Independent Director pending shareholder approval at the AGM. The company also enabled remote e-voting for its 38th AGM scheduled for 30 September 2026, enhancing shareholder participation. Additionally, the Board appointed M/s M. Goyal & Co. as Cost Auditor and M/s Bansal & Agrawal as Internal Auditor for FY 2026-27, reinforcing financial oversight. These moves reflect a structured succession plan but temporarily shift focus from operational execution to governance and approval processes.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	122	115	135	126
Operating Profit	17	20	20	25
OPM %	14.0%	17.2%	14.4%	19.6%
Net Profit	17	19	25	25
EPS	₹0.18	₹0.20	₹0.27	₹0.26

Revenue has shown volatility over the last four quarters, ranging between ₹115 crore and ₹135 crore, with operating margins fluctuating between 14.0% and 19.6%. While the latest quarter (June 2026) reported ₹126 crore revenue and ₹25 crore operating profit (OPM of 19.6%), this follows a dip in margins from the December 2025 quarter (17.2%). Net profit remained flat at ₹25 crore in both June and March 2026, suggesting pricing or cost pressures may be offsetting volume growth. The consistency in EPS (₹0.26–₹0.27) indicates stable share dilution or share count, but the lack of margin expansion despite revenue recovery suggests operational headwinds or investment timing. The financial trend does not yet reflect a clear inflection point tied to new leadership, implying execution may take time to materialize.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance on revenue, margin, or capital allocation in the reviewed filings. The most recent commentary focuses on governance and procedural updates rather than strategic outlook. With new leadership pending shareholder approval, there is no public roadmap for growth initiatives, capacity expansion, or margin improvement targets. Investors should monitor the AGM for any early signals on strategic direction, particularly regarding Rinki Ankit Bankda’s operational vision and Ankur Vijay Bankda’s financial discipline approach. Absent formal guidance, the outlook remains neutral and contingent on transition stability.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	94	94	94	94
Reserves	220	248	285	321
Borrowings	14	5	1	1
Total Liabilities	372	413	456	534
Fixed Assets	117	78	124	183
Investments	86	140	148	109
Total Assets	372	413	456	534

The balance sheet shows a stable capital structure with equity of ₹94 crore and reserves growing from ₹248 crore to ₹321 crore over the past two fiscal years, indicating retained earnings are being capitalized. Borrowings remain minimal, consistently at ₹1 crore, and total assets have risen from ₹413 crore to ₹534 crore, reflecting asset base expansion. This suggests a conservative leverage profile and reinvestment of profits into reserves rather than debt-funded growth. The strong equity cushion supports financial resilience, but the lack of debt reduction or shareholder returns implies capital is being preserved for contingencies or future opportunities rather than distributed or aggressively deployed.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	+23
Investing	-18
Financing	-68
Net Cash Flow	-63

👥 Shareholding Pattern

Category	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Promoters	50.6%	50.6%	50.6%	50.6%
FII	0.1%	0.3%	0.2%	0.3%
DII	0.0%	0.0%	0.0%	0.0%
Public	45.2%	45.0%	45.1%	44.9%
# Shareholders	4,57,364	4,42,280	4,31,690	4,22,114

Promoter holding remains stable at 50.57% across all quarters, indicating no dilution or stake sales by the Bankda family. However, FII and DII shareholding have shown a slight upward trend, rising from 0.1% to 0.35% in FII and from 0% to 0.15% in DII over the last four quarters, while public holding has marginally declined. The growing institutional interest, though still minimal in absolute terms, may signal early confidence in the company’s governance or stability. With 4.22 lakh shareholders, retail participation is broad but passive. There are no signs of significant selling pressure, but institutional accumulation remains limited and potentially opportunistic.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.63 L Cr	38.3	18.7%	14.6%	0.05
DIVISLAB	2.43 L Cr	83.2	23.0%	17.4%	0.00
TORNTPHARM	1.89 L Cr	79.1	15.1%	25.7%	1.76
ZYDUSLIFE	1.16 L Cr	25.9	16.8%	16.6%	0.43
CIPLA	1.15 L Cr	34.0	13.2%	9.8%	0.01
LAURUSLABS	1.00 L Cr	91.8	20.8%	20.6%	0.45
LUPIN	98,305	17.4	27.9%	24.7%	0.26
DRREDDY	97,741	30.3	10.1%	8.4%	0.17
MANKIND	97,467	47.7	13.9%	12.7%	0.38
AUROPHARMA	96,836	26.3	12.8%	9.8%	0.20

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Execution risk stemming from leadership transition — new Whole-time Director and CFO lack a track record of disclosed operational performance, and their approval at the AGM introduces uncertainty. 2. Margin pressure — despite revenue recovery, operating margins have not expanded consistently, suggesting cost inflation or pricing challenges may be emerging. 3. Governance dependency — the company’s financial oversight now relies on newly appointed auditors, but no changes in audit findings or internal controls have been disclosed, leaving a gap in transparency on potential weaknesses. 4. Limited institutional interest — low FII/DII participation may constrain liquidity and analyst coverage, making the stock vulnerable to retail volatility.

📋 Recent Filings

🧠 Analyst's Read

Syncom Formulations is navigating a quiet but critical inflection point: leadership succession in a family-run business introduces near-term governance uncertainty, even as financial fundamentals remain solid. The company’s strong returns and balance sheet provide resilience, but the lack of strategic clarity or forward guidance means the next few quarters will be defined by execution under new leadership. Investors should watch for early signs of operational momentum under the new MD-CFO duo, particularly in margin trends and capital allocation decisions. Until then, the stock is likely to trade on stability rather than growth expectations.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SYNCOMF

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SYNCOMF files new disclosures

Track SYNCOMF filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SYNCOMF — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd